Belapectin is under clinical development by Galectin Therapeutics and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Belapectin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Belapectin overview

Belapectin (GR-MD-02) is under development for the treatment of NASH with advanced fibrosis, liver fibrosis and decompensated liver cirrhosis, kidney fibrosis, pulmonary arterial hypertension, arrhythmias, metastatic melanoma, lung fibrosis, prostate cancer, sarcomas, breast cancer, head and neck cancer squamous cell carcinoma, non-small cell lung cancer and portal hypertension. It is administered through intravenous route and targets galectin-3. It is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer that is comprised predominantly of galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. The drug candidate is developed based on the carbohydrate technology. It is a new chemical entity. It was also under development for the treatment of diabetic nephropathy, moderate to severe plaque psoriasis, cardiovascular fibrosis and severe atopic dermatitis.

Galectin Therapeutics overview

Galectin Therapeutics is a biotechnology company. The company products include fibrosis, cancer immunotherapy, plaque psoriasis and oral galectin-3 inhibitors. It discovers, develops and commercializes therapies for fibrotic disease and cancer. Galectin Therapeutics also offers products such as GR-MD-02 and GM-CT-01. Its GR-MD-02 is a drug candidate used for treating fibrotic liver disease. and GM-CT-01 is a vaccine used to treat patients with advanced melanoma, a deadly skin cancer. The company provides research and study of the science of galectin proteins. Its products are used to treat fibrosis, galectin effects on liver fibrosis, lung fibrosis and cancer immunotherapy. Galectin Therapeutics is headquartered in Norcross, Georgia, the US.

For a complete picture of Belapectin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.